KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Halozyme Therapeutics (HALO) over the last 13 years, with Q4 2025 value amounting to $4.9 million.

  • Halozyme Therapeutics' Interest Expenses rose 817.18% to $4.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.1 million, marking a year-over-year increase of 17.13%. This contributed to the annual value of $18.1 million for FY2025, which is 17.13% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Interest Expenses stood at $4.9 million, which was up 817.18% from $4.3 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Interest Expenses high stood at $7.5 million for Q3 2022, and its period low was $1.8 million during Q2 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Interest Expenses value was $4.5 million (recorded in 2023), while the average stood at $4.0 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Interest Expenses tumbled by 6498.8% in 2021, and later soared by 32839.22% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Interest Expenses stood at $2.1 million in 2021, then surged by 122.38% to $4.6 million in 2022, then grew by 14.22% to $5.2 million in 2023, then dropped by 13.03% to $4.5 million in 2024, then rose by 8.17% to $4.9 million in 2025.
  • Its Interest Expenses stands at $4.9 million for Q4 2025, versus $4.3 million for Q3 2025 and $4.4 million for Q2 2025.